Comparing the current results to its competitors, Renovorx Inc reported Revenue increase in the 2 quarter 2026 by 115.4 % year on year. The sales growth was above Renovorx Inc 's competitors' average revenue growth of 5.16 %, achieved in the same quarter.
Renovorx Inc , slower than the average decrease reported by the company's competitors of -77.61 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -77.61 %
March 29, 2025
RenovoRx Unveils Promising Pharmacokinetic Data Amidst Challenging Market Conditions RenovoRx, a life sciences company known for its targeted oncology therapies, has taken a notable step forward by presenting new human pharmacokinetic (PK) data at the 2025 Society of Surgical Oncology (SSO) Annual Meeting. This event, held from March 27 to 29 in Tampa, Florida, served as a platform for RenovoRx to unveil its latest advancements in drug delivery through its innovative RenovoCath, an FDA-cleared device. Unpacking the Pharmacokinetic DataThe new PK data abstract, presented as ePoster P379, highlights the company s efforts to provide targeted cancer treatments that maximize therapeutic effects while minimizing s...
December 30, 2024
In the ever-evolving landscape of oncology therapeutics, RenovoRx, Inc. stands at the forefront with its groundbreaking drug-delivery therapy platform, RenovoCath. The Mountain View-based life sciences company is not only committed to developing novel targeted cancer therapies but also safeguarding its innovations through a robust intellectual property (IP) portfolio. As RenovoRx gears up for significant commercial and clinical advancements in 2025, the establishment of its IP position marks a pivotal step towards achieving its ambitious goals.RenovoRx has successfully articulated the importance of its innovative Trans-Arterial Micro-Perfusion (TAMP) therapy platform, which allows for a highly localized deli...
June 26, 2024
Pancreatic cancer is one of the deadliest types of cancer, with a notably low survival rate. However, recent advancements in medical research have brought a beacon of hope to patients and healthcare professionals alike. The University of Nebraska Medical Center has launched a pivotal Phase III clinical trial called TIGeR-PaC, aiming to investigate the effectiveness of RenovoGem in treating locally advanced pancreatic cancer. This innovative study sheds light on a potential breakthrough in the treatment landscape for this devastating disease.Understanding Pancreatic Cancer:Pancreatic cancer is a challenging condition due to its aggressive nature and often late-stage diagnosis. Locally advanced pancreatic canc...
Tiziana Life Sciences Ltd's business model focuses on the development and commercialization of innovative therapeutics in the field of immunology and oncology.
Azitra Inc is a company that operates on a business model focused on developing and commercializing microbiome-based therapeutics for various skin conditions. It aims to use the potential of the human skin microbiome to develop innovative and effective treatments.
Sanofi's business model revolves around the development, production, and distribution of pharmaceutical products. They aim to innovate and provide healthcare solutions across various therapeutic areas to improve patients' lives worldwide. Sanofi collaborates with partners and healthcare professionals to ensure effective delivery of their products and to address evolving patient needs.
AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.
Sources:
Renovorx Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Renovorx Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
